Aim: Voriconazole (VRC) overdoses are frequent and expose patients at high risk of adverse effects. 23
Introduction 45
Invasive fungal infections (IFI) are a major concern in immunocompromised patients. Among them, 46 invasive aspergillosis (IA) is particularly feared in hematological units, as mortality occurs in 19 to 47 61% of cases (1). The management of antifungal therapy of IA is challenging due to various issues 48 inherent either to inadequate exposure or drug safety. The first-line treatment of IA, voriconazole 49 (VRC), is notably concerned by such issues, as this drug exhibits both highly variable 50 pharmacokinetics and a narrow therapeutic range (2). Thus, VRC therapeutic drug monitoring (TDM) 51 is recommended to optimize treatment (2, 3), as VRC trough concentrations (Cmin) are associated 52 with both efficacy and toxicity (4). 53
Despite TDM, VRC Cmin are frequently out-of-the therapeutic range in clinical practice. Indeed, 54 subtherapeutic VRC Cmin have been found in 20 to 33% of patients (5, 6) and supratherapeutic VRC 55
Cmin in 8.8 to 23% of cases (5-7), depending on the therapeutic threshold and study population. 56
Although subtherapeutic VRC Cmin are often explained by gain-of-function single nucleotide 57 polymorphism (SNP) *17 for CYP2C19 (at least in the Caucasian population) (8-11), comedication by 58 enzymatic inducers (12), or non-observance (9), the determinants of supratherapeutic VRC Cmin 59 have been less investigated. Numerous factors, such as liver dysfunction, the use of enzymatic 60 inhibitors (13), the presence of loss-of-function SNPs for CYP2C19 (14), and inflammation (15, 16) , 61 have already been identified to be associated with increased VRC Cmin, but their impact on the 62 occurrence of VRC overdose has never been investigated. This issue is all the more relevant as 1) the 63 magnitude of the effect of each individual factor on VRC Cmin appears to be relatively weak (4) and 64
2) some of these factors, such as inflammation and genetic variants of CYP2C19, may be linked (17
Study design 70
This retrospective case-control study was conducted at Grenoble Alps University Hospital, France in a 71 hematological unit. Adult patients (> 18 years old) who experienced a VRC overdose, defined by VRC 72
Cmin determined at steady-state ≥ 4 mg/l (2) between January 2012 and December 2015 were 73 eligible. Patients were excluded in cases of prescription error, missing data, sampling before 74 pharmacokinetic steady state, suspicion of non-observance, unavailability of their DNA and also if 75 they were < 18 years (see Figure 1 for details) . 76
Risk factors of VRC overdose were assessed by comparing patients experiencing VRC overdose to 77 control patients (those with therapeutic VRC Cmin between 1 and 4 mg/l), who were randomly 78 included among all patients being followed by VRC TDM during the same period. The inclusion and 79 non-inclusion criteria for the selection of controls were similar to those for patients who experienced 80 a VRC overdose, except for the VRC Cmin. analysis, except in cases of collinearity. A stepwise procedure was used to select the final model.
6
Statistical analyses were performed using SAS v9.4 (SAS Institute Inc., Cary, NC). Significance was 121 considered for p < 0.05. 122
Results

124
Baseline characteristics of patients and potential risk factors are described in Table 1. Thirty-one  125 patients, who experienced a VRC overdose, as well as thirty-one controls without a toxic VRC Cmin, 126
were included. The median for the VRC Cmin in the cases (patients who experienced a VRC overdose) 127 was 5.3 mg/l versus 1.0 mg/l for the control group (Table 1) . 128
In univariable analysis, patients in the case group were older, exhibited higher bilirubin levels, and 129 were more frequently treated by intravenous voriconazole than those in the control group (Table 1) . 130
The proportion of allografted patients was lower in the case than control group. In addition, the 131 distribution of CRP levels was significantly different between patients who experienced a VRC 132 overdose and those who did not (table 1), with higher CRP levels for cases than controls (Figure 2) . 133
In contrast, VRC dose, sex, weight, PPI treatment, ALAT levels, underlying disease, and 134 pharmacogenetic parameters were not associated with a risk of VRC overdose, except for the 135 distribution of the CYP2C19 phenotype (table 1) or diplotype (Table E1) , which tended to differ 136 between patients who experienced a VRC overdose and those that did not (p = 0.07 and p = 0.1, 137 respectively). There was no association between pharmacogenetic parameters and risk of VRC 138 overdose, either when cytochromes CYP2C19, CYP3A4, or CYP3A5 were considered alone or 139 evaluated in the combined genetic score ( This study identified, for the first-time, inflammation (assessed by CRP levels) to be a strong 150 independent risk factor of VRC overdose in hematological patients. These data suggest that 151 hematological patients may be at increased risk of supratherapeutic VRC Cmin and associated 152 toxicity when they exhibit increased CRP levels, which is very frequent for patients with IA (24, 25). 153 Such an elevated CRP-level associated risk of VRC overdose is in accordance with several previous 154 studies reporting positive associations between elevated CRP levels and high VRC Cmin (15, 16, 26-155 28). This is probably related to inflammation-induced phenoconversion, during which 156 proinflammatory cytokines, such as interleukin-6, reduce both CYP3A4 and CYP2C19 expression and 157 activity (29). Hence, it is probable that inflammation rapidly inhibits VRC metabolism by reducing 158 CYP3A4 and CYP2C19 activities, which ultimately results in increased VRC Cmin and greater risk of 159 overdose. 160 PPI cotreatment, advanced age, and high bilirubin levels, which have already been reported to be 161 associated with increased VRC Cmin, were not associated (PPI treatment) or only associated in 162 univariable analysis (age and hepatic dysfunction) with a risk of VRC overdose in this study. Similarly, 163 none of the pharmacogenetic parameters, including the CYP2C19 phenotype or the CYP3A4 and 164 CYP3A5 genotypes, considered alone or in a combined genetic score, were associated with VRC 165
overdose. This result is surprising, as numerous previous studies have demonstrated that the loss-of-166 function SNPs affecting CYP2C19 (*2 or *3) (30-32) or CYP3A4 (*22) (11, 33-36) were associated 167 with elevated VRC Cmin. These discrepancies may be explained by the relatively low number of 168 patients included, which limited the statistical power of our study and increased the width of the 169 confidence intervals. Despite this limitation, our work clearly demonstrates that inflammation, 170
shown by high CRP levels, is the sole independent risk factor of VRC overdose in French 171 hematological patients, completely masking the effects of other potential risk factors. 172
In addition, we investigated the possible link between CRP levels and the CYP2C19 phenotype by 173 additional statistical analyses (see Table E2 and Figure E1 in supplemental data). Although there was 174 no association between CRP and pharmacogenetic parameters (both CYP2C19 phenotype and class 175 of combined genetic score), the absence of a link cannot be completely ruled out as CRP and IL-6 176 levels have been reported to be elevated in poor CYP2C19 metabolizers (17-19). These findings 177
suggest that an association between loss-of-function SNPs of CYP2C19 and elevated VRC Cmin (8, 30, 178 37) could result in reduced VRC metabolism due to diminished CYP2C19 activity (direct effect), as 179 well as an increase in IL-6 levels, and hence down-regulation of CYP2C19 and CYP3A4 activities 180 (indirect effect). Further studies should be performed to clarify the respective roles of inflammation 181 and pharmacogenetic determinants on VRC Cmin and explore their eventual link, especially as the 182 effect of inflammation on VRC Cmin may be modulated by pharmacogenomic parameters (15, 38). 183
This study had several limitations. First, it was retrospective, performed in a single center, and only a 184 small number of subjects was included. Second, data on the clinical consequences of VRC overdose in 185 terms of side effects, treatment discontinuation, and efficacy of treatment was absent. This aspect 186 may be particularly important to explore in the future, as studies have already shown that elevated 187 pro-inflammatory cytokine levels are a predictor of poor outcome in invasive aspergillosis (24, 25). 188
In conclusion, our study identified inflammation as the main risk factor of VRC overdose in French 189 hematological patients, whereas pharmacogenetic determinants do not appear to be involved. These alleles were heterozygous for all patients of this cohort, except for two patients who did not experience a VRC overdose, who had two alleles *1 for CYP3A5. d based on the classification proposed by Moriyama et al. (21) . Based on these guidelines, patients with CYP2C419*2/*17 (one patient in the group of VRC overdose and two patients in the control group) were considered to be intermediate metabolizers. See supplemental data for a detailed description of the CYP2C19 diplotypes (Table E1) 
